Advertisement
Advertisement
U.S. markets open in 8 hours 18 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Tetra Bio-Pharma Inc. (TBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.06500.0000 (0.00%)
At close: 03:50PM EDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0650
Open0.0650
Bid0.0600 x N/A
Ask0.0650 x N/A
Day's Range0.0600 - 0.0650
52 Week Range0.0500 - 0.3250
Volume118,435
Avg. Volume211,980
Market Cap27.519M
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-0.1100
Earnings DateJul 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TBP.TO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • CNW Group

      IIROC Trading Halt - TBP.WT.A

      The following issues have been halted by IIROC:

    • PR Newswire

      Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug

      Akanda Corp. ("Akanda") (NASDAQ: AKAN) and Tetra Bio-Pharma ("Tetra") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), today jointly announced that Akanda will supply Tetra with pharmaceutical grade cannabis flower in a microdose cap form, for use in a Storz & Bickel Mighty Medic Vaporizer for global commercialization of Tetra's QIXLEEFTM and related products. In addition, Akanda will act as a Contract Development and Manufacturing Organization (CDMO) for Tetra's clinical drug and commercial supply progra

    • PR Newswire

      Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announces the launch of its new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd' ("TBP-AU"), an Australian-based research company focused on the execution of clinical trials in Australia. This represents Tetra's second foreign subsidiary and is in line with the Company's global expansion strategy for QIXLEEF™, and other future drug can

    Advertisement
    Advertisement